Overview of Tivicay
Tivicay is the first once daily, unboosted integrase inhibitor.*
Tivicay is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults, adolescents and children above 6 years of age. Tivicay is contraindicated in patients with hypersensitivity to dolutegravir or to any of the excipients, and with co-administration with dofetilide.
Tivicay has been extensively studied in a clinical programme involving 3,041 patients across five phase III trials (SINGLE, SPRING-2, FLAMINGO, SAILING, VIKING-3).[2-9]
Reasons to rethink first line treatment with Tivicay for patients with HIV-1:
Make dolutegravir▼ your core agent
A journey through ART innovation – how 3rd agents have become core to HIV therapy.
* Tivicay is dosed 50 mg once daily for patients without documented or clinically suspected resistance to the integrase class. Tivicay should be administered twice daily in this population when co-administered with some medicines (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin). 
Tivicay is dosed 50 mg twice daily for patients with resistance to the integrase class (documented or clinically suspected). Co-administration of Tivicay with some medicines should be avoided in this population (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin). In the presence of integrase inhibitor resistance, there are insufficient data to recommend a dose for dolutegravir in adolescents and children. 
- TIVICAY (dolutegravir) Summary of Product Characteristics.
- Walmsley S, et al. N Engl J Med. 2013;369(19):1807-1818.
- Raffi F, et al. Lancet. 2013;381(9868):735-743.
- Raffi F, et al. Lancet Infect Dis. 2013;13(11):927-935.
- Clotet B, et al. Lancet. 2014;383(9936):2222-2231.
- Cahn P, et al. Lancet. 2013;382(9893):700-708.
- Castagna A, et al. J Infect Dis. 2014; 210: 354-362.
- Pappa K, et al. Oral presentation at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC, USA.
- Molina J-M, et al. J Int AIDS Soc 2014; 17(Suppl 3): 19490.
- European AIDS Clinical Society. Guidelines. Version 7.1. November 2014. Available at: http://eacsociety.org/Guidelines.aspx Last accessed December 2014.